Therapeutic implications of constitutive activity of receptors: The example of the histamine H3 receptor

Journal of Neural Transmission, Supplement

Volumn , Issue 64, 2003, Pages 1-16

  Schwartz, J C ^a   Morisset, S ^a   Rouleau, A ^a   Ligneau, X ^b   Gbahou, F ^a   Tardivel Lacombe, J ^a   Stark, H ^c   Schunack, W ^c   Ganellin, C R ^d   Arrang, J M ^a  

^a CENTRE PAUL BROCA   (France)

^b Laboratoire Bioprojet   (France)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ANTIHISTAMINIC AGENT; CALCIMYCIN; CIMETIDINE; CIPROXIFAN; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; ETHER DERIVATIVE; FAMOTIDINE; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR; IMETIT; MEPYRAMINE; METHAMPHETAMINE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NEUROLEPTIC AGENT; TACRINE; THIOPERAMIDE; YOHIMBINE;

COGNITION; CONFERENCE PAPER; CONFORMATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HALLUCINATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR RELEASE; MENTAL DISEASE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; POPULATION RESEARCH; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN BINDING; PSYCHOSIS; RECEPTOR BLOCKING; SYNAPTIC INHIBITION; ANIMAL; BRAIN; COGNITIVE DEFECT; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; BRAIN; COGNITION; COGNITION DISORDERS; HUMANS; RECEPTORS, HISTAMINE H3;

EID: 0043245853     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6020-6_1     Document Type: Conference Paper

References (47)

1. 2 receptor. J Neurochem 71: 799-807
2. 3) of histamine receptor. Nature 302: 832-837
3. 3-receptors. Nature 327: 117-123
4. 35S]-GTPgS binding isotherms. Neuropharmacol 40: 57-64
5. 1 receptor antagonists. Eur J Pharmacol 387: R5-R7
6. Chen G, Way J, Armour S, Watson C, Queen K, Jayawickreme CK, Chen WJ, Kenakin T (2000) Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 57: 125-134
7. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M (1994) Inverse agonism activity of β-adrenergic antagonists. Mol Pharmacol 45: 490-499
8. 4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol 55: 910-920
9. 3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol 259: 107-114
10. 3-receptors in rat cerebral cortical membranes. Br J Pharmacol 114: 357-362
11. 35S]GTP gamma[S] binding to pertussis toxin. Eur J Pharmacol 296: 223-225
12. Costa T, Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86: 7321-7325
13. Costa T, Ogino Y, Munson PJ, Onaran O, Rodbard D (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41: 549-560
14. de Ligt RAF, Kourounakis AP, Ijzerman AP (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130: 1-12
15. 3-receptor ligands on various biochemical indices of histaminergic neuron activity in rat brain. Eur J Pharmacol 164: 1-11
16. 3 receptor. J Neural Transm 103: 1163-1175
17. Ito C, Onodera K, Sakurai E, Sato M, Watanabe T (1996) Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine. J Pharmacol Exp Ther 279: 271-276
18. 2 receptor gene variants: lack of association with schizophrenia. Mol Psychiat 5: 159-164
19. Kenakin TP (1997) Pharmacological analysis of drug receptor interaction. Lippincott-Raven, New York
20. Khateb A, Fort P, Pegna A, Jones BE, Muhlethaler M (1995) Cholinergic nucleus basilis neurons are excited by histamine in vitro. Neuroscience 69: 495-506
21. 3 receptor-dependent G protein activation in rat brain tissue sections. J Neurochem 71: 808-816
22. Lefkowitz RJ, Cotecchia S, Samama P, Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14: 303-307
23. Leurs R, Smit MJ, Alewijnse AE, Timmerman H (1998) Agonist-independent regulation of constitutively active G-protein-coupled receptors. Trends Biochem Sci 23: 418-422
24. 3 receptors. J Pharmacol Exp Ther 271: 452-459
25. 3-receptor antagonist. J Pharmacol Exp Ther 287: 658-666
26. 3 receptor. Mol Pharmacol 55: 1101-1107
27. Ma H, Green RD (1992) Modulation of cardiac cyclic AMP metabolism by adenosine receptor agonists and antagonists. Mol Pharmacol 42: 831-837
28. Milligan G, Bond R (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18: 468-474
29. Milligan G, Bond R, Lee M (1995) Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 16: 10-13
30. Morisset S, Traiffort E, Schwartz JC (1996) Inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity. Eur J Pharmacol 315: R1-R2
31. 2A receptor blockade. J Pharmacol Exp Ther 288: 590-596
32. 3 receptors regulates histamine neurons in brain. Nature 408: 860-864
33. 1A receptors as a function of receptor: G-protein stoichiometry. Neuropharmacol 36: 451-459
34. 1B receptor/G-protein stoichiometry. Mol Pharmacol 58: 1042-1049
35. 2 receptors? J Neural Transm 92: 213-220
36. Panula P, Rinne J, Kuokkanen K, Eriksson KS, Sallmen T, Kalimo H, Relja M (1998) Neuronal histamine deficit in Alzheimer's disease. Neuroscience 82: 993-997
37. 1A receptor agonists in recombinant cell lines: modulation of apparent efficacy by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol 356: 551-561
38. αo protein coexpression: evidence for inverse agonism. J Pharmacol Exp Ther 292: 654-663
39. Pozvek G, Hilton JM, Quiza M, Houssami S, Sexton PM (1997) Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system. Mol Pharmacol 51: 658-665
40. Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ (1995) Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationship to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 14: 93-104
41. 3 receptors. Br J Pharmacol 135: 383-392
42. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268: 4625-4636
43. 1-antagonists. Prog Neurobiol 52: 145-157
44. 1 adenosine receptors stably expressed in chinese hamster ovary cells. Mol Pharmacol 53: 886-893
45. Strange P (2002) Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 23: 89-95
46. 35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J Pharmacol Exp Ther 283: 1276-1284
47. 3 receptor: evidence for two isoforms. NeuroReport 11: 755-759